肾移植候选者与受者的代谢风险特征
本文综述肾移植候选者与受者中常见代谢风险因素(糖代谢异常、肥胖、代谢综合征、血脂异常、代谢性骨病、高尿酸血症等)的评估与处理。在候选者中这些因素可能阻碍其进入移植等待名单并增加围手术期风险;在受者中则与带功能移植物死亡率和长期移植物存活率降低相关。文章强调应积极控制导致动脉钙化的代谢异常,受者中由抗排斥治疗不良反应所致的代谢异常可通过生活方式改变和合理用药有效控制。
要点
- 肾移植候选者应积极评估并控制代谢异常,以减少等待期并发症和移植准入障碍
- 受者中代谢风险因素与带功能移植物死亡率和长期移植物存活率降低相关
- 受者代谢异常可由抗排斥治疗不良反应引起,生活方式改变和合理用药可有效控制
核心结论
- 对每位潜在肾移植候选者应尽力控制导致动脉钙化的代谢异常,因其可能阻碍移植准入并损害移植结局。
- 受者中由抗排斥治疗不良反应所致的代谢异常可通过生活方式改变和合理用药有效控制。
研究设计与样本
- 本文为综述,聚焦肾移植候选者与受者代谢风险因素的评估与治疗策略。
主要发现
- 糖代谢异常、肥胖、代谢综合征、血脂异常、代谢性骨病、高尿酸血症等在候选者和受者中均常见。
- 候选者中这些风险因素可能增加等待期并发症风险、延长等待名单时间并危及移植适宜性或增加围手术期严重并发症风险。
- 受者中代谢风险因素可能与带功能移植物死亡率增加和长期移植物存活率降低相关。
- 多数受者无使用经肾排泄药物的禁忌,但可能与抗排斥药物发生药代动力学相互作用。
临床怎么用
- 对每位潜在候选者应评估并积极控制代谢异常,尤其是导致动脉钙化的因素。
- 受者中应通过生活方式改变和合理用药管理糖代谢异常和血脂异常等代谢问题。
- 使用经肾排泄药物时需注意与抗排斥药物的药代动力学相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic risk factors of cardiovascular disease such as abnormal glucose regulation, obesity and metabolic syndrome, dyslipidaemia, metabolic bone disease, hyperuricaemia and other less traditional abnormalities are common in both kidney transplant candidates and recipients. In kidney transplant candidates, the presence of these risk factors may impede patient access to transplantation by increasing the risk of developing comorbidities while on the waiting list, prolonging the time to wait-listing and, in some patients, eventually jeopardizing their suitability for kidney transplantation or increasing the risk of severe perioperative complications. In transplant recipients, metabolic risk factors may be associated with increased mortality with a functioning graft and with reduced long-term renal graft survival. Although most transplant recipients have no contraindication to the use of drugs that undergo renal excretion, they may be at risk of drug-to-drug pharmacokinetic interactions with anti-rejection medicines. In this review, we have highlighted the main objectives of evaluating the metabolic abnormalities in transplant candidates and recipients, how this evaluation should be carried out in practice and what currently the most valuable treatment strategies are for modifying the associated risks. We conclude that, for every potential transplant candidate, every effort should be made to control metabolic abnormalities causing arterial calcification, which may impede access to transplantation and impair transplant outcome. In transplant recipients, metabolic abnormalities that result from adverse effects of anti-rejection therapy may be effectively controlled by lifestyle changes and judicious use of drugs for the treatment of abnormal glucose metabolism and dyslipidaemia.
引用
- Piotti G, Gandolfini I, Palmisano A, et al. Metabolic risk profile in kidney transplant candidates and recipients. Nephrol Dial Transplant. 2019. PMID: 29800310. doi:10.1093/ndt/gfy151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。